睿知中国医院研究地图
候选清单

正在招募肺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心同济大学附属东方医院Shanghai East Hospital, Tongji University上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06437509,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Newly diagnosed patients with extensive-stage small cell lung cancer confirmed by histopathology and / or cytology;

    入选标准第 5 条

  3. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;

    入选标准第 9 条

  4. ECOG score 0-1;

    入选标准第 4 条

  5. No blood transfusion and no use of cell growth factors and/or platelet-raising drugs within 14 days before screening, and the organ function level must meet the requirements;

    入选标准第 8 条

  6. At least one measurable lesion meeting the RECIST v1.1 definition was required;

    入选标准第 7 条

  7. Other malignancies that have progressed or require treatment within 5 years prior to the first dose;

    排除标准第 9 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06437509,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Subject volunteered to participate in the study and signed an informed consent;
  2. Male or female aged ≥18 years and ≤75 years;
  3. Expected survival time ≥3 months;
  4. ECOG score 0-1;
  5. Newly diagnosed patients with extensive-stage small cell lung cancer confirmed by histopathology and / or cytology;
  6. A archived tumor tissue sample or fresh tissue sample of the primary or metastatic lesion must be provided within 3 years;
  7. At least one measurable lesion meeting the RECIST v1.1 definition was required;
  8. No blood transfusion and no use of cell growth factors and/or platelet-raising drugs within 14 days before screening, and the organ function level must meet the requirements;
  9. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
  10. For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, a serum or urine pregnancy test must be negative, and the patient must not be lactating; All enrolled patients should take adequate barrier contraception during the entire treatment cycle and for 6 months after the end of treatment.

排除标准:Exclusion Criteria:

  1. Prior use of ADC drug therapy with small molecule toxins as topoisomerase I inhibitors;
  2. Prior treatment with any systemic anti-tumor regimen for extensive-stage small cell lung cancer;
  3. Pathology suggested small cell carcinoma containing non-small cell carcinoma components;
  4. Subjects had used immunomodulatory drugs within 14 days before the first use of the study drug ;
  5. Screening the history of severe cardiovascular and cerebrovascular diseases in the first half of the year ;
  6. QT interval prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia ;
  7. Active autoimmune diseases and inflammatory diseases ;
  8. Receiving long-term systemic corticosteroid therapy or equivalent anti-inflammatory active drugs or any form of immunosuppressive therapy prior to the first dose;
  9. Other malignancies that have progressed or require treatment within 5 years prior to the first dose;
  10. Have ILD requiring steroid therapy, or currently have ILD, or suspected ILD at screening;
  11. Prior to initiation of study treatment, there were: a) poorly controlled diabetes mellitus; b) with severe complications of diabetes; c) glycosylated hemoglobin levels of 8% or more; d) hypertension that is poorly controlled by two antihypertensive drugs; e) history of hypertensive crisis or hypertensive encephalopathy;
  12. Unstable thrombotic events requiring therapeutic intervention within 6 months prior to screening; Except for infusion set-related thrombosis;
  13. Concurrent pulmonary disease leading to severe clinical impairment of respiratory function;
  14. Patients with active central nervous system metastases;
  15. Patients with large serosal effusions, or symptomatic serosal effusions, or poorly controlled serosal effusions;
  16. History of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any excipient component of the experimental drug;
  17. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation;
  18. Positive human immunodeficiency virus antibody, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
  19. Severe infection within 4 weeks prior to first dose of study drug; Lung infection or active lung inflammation within 4 weeks;
  20. Have participated in another clinical trial within 4 weeks prior to the first dose;
  21. Have a history of psychotropic substance abuse and cannot be abstained from or have a history of severe neurological or psychiatric disorders;
  22. Imaging examination showed that the tumor had invaded or encapsulated the large blood vessels in the chest;
  23. Severe and non-healing wounds, ulcers, or fractures within 4 weeks prior to signing the informed policy;
  24. Clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to signing the informed policy;
  25. Subjects who are scheduled to receive or receive a live vaccine within 28 days prior to the first dose;
  26. Other conditions that the investigator considers unsuitable to participate in this clinical trial.

引自 ClinicalTrials.gov, NCT06437509, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06437509,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06437509